(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 29.34% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 280.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.03%.
Alvotech's revenue in 2025 is $573,350,000.On average, 7 Wall Street analysts forecast ALVO's revenue for 2025 to be $206,865,774,118, with the lowest ALVO revenue forecast at $192,547,701,091, and the highest ALVO revenue forecast at $224,708,056,196. On average, 6 Wall Street analysts forecast ALVO's revenue for 2026 to be $288,673,541,089, with the lowest ALVO revenue forecast at $261,121,767,052, and the highest ALVO revenue forecast at $314,093,963,232.
In 2027, ALVO is forecast to generate $400,407,482,890 in revenue, with the lowest revenue forecast at $320,637,587,466 and the highest revenue forecast at $471,140,944,848.